Compare Adaptive Biotechnologies Corp (ADPT) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ishares Msci Brazil ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Ishares Msci Brazil ETF trades at $34.4. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | EWZ | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $41.75 |
52-Week Low | $10.24 | $26.52 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EWZ, the iShares MSCI Brazil ETF, trades at $34.92, up 1.42% over 24 hours, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights potential as a 2026 sleeper trade if rate cuts proceed, with exposure to Brazilian equities trading at a forward P/E of 9.6x as of Seeking Alpha on 2026-05-05.
Outlook is positive due to asymmetric upside from rate cuts, election repricing, and commodity tailwinds, but risks include Brazil's economic volatility and dependency on Petrobras/Vale dividends. Investors face currency and political uncertainties, though institutional interest remains with new positions like Altfest's $4.72 million investment in Q4 2025 per Defense World on 2026-04-12.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
